Prognostic Relevance of Biological Subtype in Breast Cancer

• Conditions: Breast Cancer

• Registration Number: NCT02063906
• Lead Sponsor: Samsung Medical Center

Brief Summary

Recently, the investigators face "on the edges" for treatment decision to decide adjuvant systemic treatment, especially for patients who show discordance between stage and tumor biology. The aim of this study was to compare the prognostic relevance of the TNM staging system and intrinsic subtype in breast cancer patients who received curative surgery.

Detailed Description

Identified patients who received curative surgery for stage I-III breast cancer and had available data on immunohistochemistry profiles including hormone receptor status (HR) status, human epidermal growth factor receptor 2 (HER2) status, and Ki 67 staining at Samsung Medical Center from January 2004 to September 2008. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS).

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2014-02
• Study First Submitted: 2014-02-12
• Study First Submitted QC: 2014-02-13
• Study First Posted: 2014-02-17
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-27
• Last Update Posted: 2017-05-01
• Primary Completion: 2018-04
• Study Completion: 2019-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 202

Inclusion Criteria

• patients who received curative surgery
• stage I-III breast cancer
• between January 2004 and September 2008
• had available immunohistochemistry profiles.

exclusion Criteria:

• age <18 years old
• microinvasive carcinoma of breast

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival	1 year	was measured from the first date of diagnosis of breast cancer to the date of death or the last follow-up visit

Secondary Outcome Measures

Name	Time	Method
Recurrence-free survival	1 Year	was defined as the time from the date of curative resection to the date when breast cancer recurred, irrespective of locoregional recurrences including ipsilateral and contralateral breast recurrences or distant metastases.

Trial Locations

Locations (1)

Samsung Medical Center, Sungkyunkwan University School of Medicine; 🇰🇷 Seoul, Korea, Republic of